Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

NCT00962767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myelocytic, Acute

Interventions

DRUG: gemtuzumab ozogamicin
DRUG: ATRA plus 6-MP and MTX

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer